Consumer's Guide to Curcumin and Turmeric

Curcumin (Turmeric) Suppresses Arthritis Symptoms

Curcumin (turmeric) is well known for its anti-inflammatory properties. Now researchers have found curcumin may also help underlying causes of inflammation and reduce damage to bone and cartilage. (2, 8)

Curcumin is Superior to Steroidal (SAIDS) and Non-Steriodal (NSAIDS) Anti-Inflammatory Drugs

Research shows curcumin acts as a scavenger of nitric oxide and inhibits COX-2, a pro-inflammatory substance. Also a potent scavenger of superoxide, the anti-inflammatory activity and superoxide scavenging property of curcumin are proven correlated. Clinically, curcumin has worked as well as cortisone or phenylbutazone for rheumatoid arthritis, osteoarthritis and post-operative inflammation. (1-5)

Compare the effect of curcumin and NSAID phenylbutazone on reduction of post-operative inflammation

Curcumin reduces acute pain and inflammation better than NSAID phenylbutazone (5)

The anti-inflammatory activity of curcumin was evaluated in a group of patients who underwent surgery or suffered from trauma. A double-blind controlled-trial in which three groups received curcumin (400 mg/day), a placebo, or phenylbutazone (100 mg/day) for five consecutive days after surgery. Treatment with curcumin resulted in reduced inflammation more effectively than phenylbutazone. (5)

Phenylbutazone is a powerful analgesic (painkiller) and an NSAID (nonsteroidal anti-inflammatory drug). Unlike NSAIDS, which have dangerous side-effects and black-box warnings, curcumin is safe and has no side-effects, even at doses up to 8,000 mg per day. (10, 11)

Curcumin also inhibits COXs better than indomethacin, a currently prescribed mixed COX inhibitor. (6, 7)

A double-blind crossover study in patients with "definite" rheumatoid arthritis compared the antirheumatic activity of curcumin (1200 mg/day) with phenylbutazone, a corticosteroids drug (300 mg/day). The curcumin therapy resulted in "significant" improvements over corticosteroids. Curcumin better relieved morning stiffness and joint swelling, and improved walking time. Best of all, curcumin was well-tolerated and produced no side-effects. (2, 8)

Curcumin Supresses Systemic Inflammation Markers

Another published study found curcumin substantially suppresses systemic inflammation markers MMP-3 by 48% to 99%, and MMP-13 by 45% to 97%. Researchers concluded curcumin could be useful for reducing cartilage degradation (resorption by MMPs) in arthritis. (2 ,9)

How Much Curcumin Can You Absorb?

Unfortunately, pure curcumin (including all known curcuminoids) is very poorly absorbed into your bloodstream after oral ingestion due to rapid metabolism in the liver and intestinal wall, and rapid systemic elimination. (12, 13)

Oral Curcumin Absorption

Until recently, extremely high doses of curcumin were required to obtain desired blood levels. Scientists have long sought a more bioavailable form of curcumin to maximize curcumin's efficacy. In fact, most consumers may not realize many research studies achieved effective blood levels of curcumin by intravenous injections--directly into the veins. While it may be available in other parts of the world, injectable forms of curcumin are not sold in the United States.

500 milligrams of BIOMOR Curcumin is equivalent to up to 4,000 milligrams other curcumin 95 percent, and is equivalent to 3,185 milligrams of curcumin with piperine.

Each capsule of BIOMOR® contains 500 mg of
Faster-Acting, Longer-Lasting, Best-Bioavailable Curcumin

BIOMOR® Curcumin provides curcumin blood levels up to 800% greater than other standardized 95% curcumin (14) and 637% greater bioavailability than curcumin blended with piperine and lecithin. (15)

The good news is a new, patented (16) curcumin product dramatically increases blood plasma curcumin to levels not previously seen through oral supplementation. (This impressive rise in bioavailability is achieved without piperine.) The new curcumin relies upon a specific ratio of curcuminoids reconstituted with a high content of sesquiterpenoids (turmeric essential oil compounds).

This new, patented (16) manufacturing technology increases absorption of curcumin up to a remarkable 800% greater than other standardized curcumin preparations. (14)

(This superior bioavailability is achieved without piperine.)

  • 1. Balakrishnan, K.V. "Postharvest Technology and Processing of Turmeric," Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 2. Bharat, B.A., et al. "Curcumin--Biological and Medicinal Properties,"
  • Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 3. Goel A., et al. "Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells," Cancer Lett.: 172(2), 111-1118, 2001.
  • 4. Zhang F., et al. "Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells," Carcinogenesis: 20(3), 445-51, 1999.
  • 5. Satoskar R.R., et al. "Evaluation of anti-inflammatory property of curcumin in patients with post-operative inflammation," Int. J. Clin. Pharmacol. Ther. Toxicol.: 24(12), 651-4, 1986.
  • 6. Kulkarni, A.P., et al. "Curcumin Inhibits the Classical and the Alternate Pathways of Complement Activation," Ann. N.Y. Acad. Sci.: 1056, 100-112, 2005.
  • 7. Kotwal, G.J., et al. Natural Products and Molecular Therapy, First International Conference, New York, NY: Annals of the New York Academy of Sciences, Vol. 1056, 2005.
  • 8. Deodhar, S.D. et al., "Preliminary study on antirheumatic activity of curcumin," Indian J. Med. Res.: 71, 632-634, 1980.
  • 9. Liacini, S., et al., "Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappaB) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes," Matrix Biol.: 21(3), 251-262, 2002.
  • 10. Sarker, S.D., et al. "Bioactivity of Turmeric," Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 11. Cheng, A.L., et al. "Phase I clinical trial of curcumin, a chemoprotective agent, in patients with high-risk or pre-malignant lesions. Anti-cancer Res. 2001; July-Aug 21:2895-2900:
  • 12. Bharat, B.A., et al. "Curcumin--Biological and Medicinal Properties," Turmeric: The genus Curcuma; Medicinal and aromatic plants--industrial profiles, edited by Ravindran, P.N., et al. Boca Raton, FL: CRC Press, 2007.
  • 13. Anand, P., et al. "Bioavailability of Curcumin: Problems and Promises," Mol. Pharmaceutics: 2007, 4(6), pp. 807-818: (Cytokine Research Laboratory and Pharmaceutical Development Center, Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.)
  • 14. Benny, M., et al. Spice India: Vol. 19, No. 9, pp. 11-15, 2006.
  • 15. Antony, B., et al. "Evaluation of a novel bioenhanced curcumin," Indian Journal of Pharmaceutical Sciences: Jul-Aug, pp. 445-50, 2008.
  • 16. Antony, B. "Composition to Enhance the Bioavailablity of Curcumin," U.S. Patent Nos. 7,736,679, 7,883,728, 7,879,373 (2011).

BioMor Curcumin

Faster-Acting, Longer-Lasting, Best-Bioavailable Curcumin

Healthy Source
Old-Fashioned Personal Service: 1-800-200-1203

  • © 2008-2014 Healthy Source, LLC. All rights reserved.
Statements made herein have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.